Related Experiment Videos
Second cancer after treatment of malignant germ-cell tumors
S D Fosså1, E H Wanderås, K Heimdal
1Department of Medical Oncology and Radiotherapy, Norwegian Radium Hospital, Oslo.
Abstract:
Patients cured of a malignant germ-cell tumor are at a significantly increased relative risk (RR, 1.3-2.1) of developing a new malignancy, the most frequent second cancer being a new germ-cell cancer. The exact role of modern treatment of germ-cell malignancies as an etiological factor of a subsequent cancer has not yet been defined. The relative risk of developing a new non-germ-cell cancer, however, seems especially high after intensive cytotoxic treatment.
Insights
Patients cured of germ-cell tumors face a higher risk of developing new cancers, particularly another germ-cell cancer. Intensive treatments may increase the risk of non-germ-cell cancers.
Area of Science:
- Oncology
- Cancer Research
- Epidemiology
Background:
- Malignant germ-cell tumors (GCTs) are rare but can be aggressive.
- Survivors of GCTs have an elevated risk of subsequent malignancies.
- The specific impact of GCT treatments on secondary cancer development requires further investigation.
Purpose of the Study:
- To summarize the risk of developing new malignancies after GCT treatment.
- To identify common second cancer types in GCT survivors.
- To explore the potential etiological role of GCT treatments in secondary cancer development.
Main Methods:
- Review of existing literature and epidemiological data.
- Analysis of relative risk (RR) for second cancer development.
- Comparison of cancer risks based on treatment intensity.
Main Results:
- GCT survivors exhibit a significantly increased relative risk (1.3-2.1) of new malignancies.
- The most frequent second cancer observed is a new germ-cell cancer.
- Intensive cytotoxic treatments appear to be associated with a particularly high risk of non-germ-cell cancers.
Conclusions:
- Germ-cell tumor survivors have a heightened risk for subsequent cancers.
- Further research is needed to elucidate the precise role of GCT treatments in secondary cancer etiology.
- Treatment protocols may need to consider long-term risks for non-germ-cell cancer development.